CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
MK-8291 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02336555
NCT02336555Phase 1Completed
CompareCT.gov

A Randomized Clinical Trial to Study the Efficacy, Safety, and Tolerability of MK-8291 in Subjects With Post-Herpetic Neuralgia With Allodynia

Merck Sharp & Dohme LLC·interventional·Posted Jan 13, 2015·Updated Dec 9, 2019

In Brief

A Phase 1 clinical trial evaluating MK-8291 and Placebo for Postherpetic Neuralgia. Completed, enrolled 35 participants.

Detailed Summary

This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia. The primary hypothesis is that when compared to placebo, treatment with MK-8291 reduces the change from Baseline in participant-reported pain intensity by 1 on an 11-point numeric rating scale.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 13, 2015
Enrollment StartMar 12, 2015
Primary CompletionFeb 29, 2016
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.5 years ago

Interventions

MK-8291drug

MK-8291 oral tablets

Placebodrug

Placebo oral tablets